Gelteq (GELS) Q4 2024 earnings summary

Executive summary

• Focused on developing and commercializing gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and sports products, leveraging proprietary technology and patents across multiple verticals.

• Revenue for FY2024 was nil due to undelivered orders from customers with cash flow difficulties, but deferred revenue increased to AUD $125,359, with plans to fulfill orders in FY2025.

• Completed IPO in October 2024, raising $5.2 million (AUD $7.95 million) to support growth and operations.

Financial highlights

• FY2024 revenue: AUD $0 (FY2023: AUD $79,843); deferred revenue: AUD $125,359 (FY2023: AUD $85,359).

• Net loss for FY2024: AUD $3,546,195 (FY2023: AUD $3,506,220).

• Cash and cash equivalents at June 30, 2024: AUD $24,522 (June 30, 2023: AUD $399,224).

• Intangible assets: AUD $20,437,958, representing 98.6% of total assets.

• Current liabilities exceeded current assets by AUD $3,589,543 at June 30, 2024.

Outlook and guidance

• Plans to deliver 400,000 units in FY2025 from prior orders and expects significant revenue growth as customers resolve cash flow issues.

• Focus on expanding sales in animal health, nutraceutical, sports, OTC, and pharmaceutical verticals, with new hires and increased marketing.

• Ongoing investment in R&D, with clinical trials planned for gel-based drug delivery products targeting FDA approval via the 505(b)(2) pathway.